Skip to Main Content

Paper Details

Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
BMC Pharmacol Toxicol
21
2014
AZD6482, BIBW2992, Bosutinib, Docetaxel, Gefitinib, HNSCC, HNSCC cell lines, HNSCC cells, HNSCC lines, HPV-positive lines, PI3K, PIK3CA, PIK3CA mutations, cancer, cell line, cell line pool, head and neck cancer, head and neck squamous cell cancer, human papillomavirus, mutant tumors, non-HNSCC lines, patient, patients, tumors
Antineoplastic Agents, Carcinoma, Squamous Cell, Cell Line, Class I Phosphatidylinositol 3-Kinases, Drug Resistance, Neoplasm, Gene Dosage, Head and Neck Neoplasms, High-Throughput Screening Assays, Mutation, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors, Squamous Cell Carcinoma of Head and Neck
Author NameAffiliation
Anthony C NicholsWestern University
  • 1 - 1

Datasets

Release 1.2